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ABSTRACT
Inﬂammation is implicated in the progressive nature of neu-
rodegenerative diseases, such as Parkinson’s disease, but
the mechanisms are poorly understood. A single systemic li-
popolysaccharide (LPS, 5 mg/kg, i.p.) or tumor necrosis fac-
tor alpha (TNFa, 0.25 mg/kg, i.p.) injection was adminis-
tered in adult wild-type mice and in mice lacking TNFa
receptors (TNF R1/R22/2) to discern the mechanisms of
inﬂammation transfer from the periphery to the brain and
the neurodegenerative consequences. Systemic LPS admin-
istration resulted in rapid brain TNFa increase that
remained elevated for 10 months, while peripheral TNFa
(serum and liver) had subsided by 9 h (serum) and 1 week
(liver). Systemic TNFa and LPS administration activated
microglia and increased expression of brain pro-inﬂamma-
tory factors (i.e., TNFa, MCP-1, IL-1b, and NF-jB p65) in
wild-type mice, but not in TNF R1/R22/2 mice. Further, LPS
reduced the number of tyrosine hydroxylase-immunoreac-
tive neurons in the substantia nigra (SN) by 23% at
7-months post-treatment, which progressed to 47% at
10 months. Together, these data demonstrate that through
TNFa, peripheral inﬂammation in adult animals can: (1)
activate brain microglia to produce chronically elevated pro-
inﬂammatory factors; (2) induce delayed and progressive
loss of DA neurons in the SN. These ﬁndings provide valua-
ble insight into the potential pathogenesis and self-propel-
ling nature of Parkinson’s disease. VC 2007 Wiley-Liss, Inc.
INTRODUCTION
Inﬂammation and microglial activation is a common
component of the pathogenesis for multiple neurodegen-
erative diseases, including Alzheimer’s disease, Parkin-
son’s disease (PD), Huntington’s disease, Multiple sclero-
sis, and Amyotrophic lateral sclerosis (Nguyen et al.,
2002). Microglia, the resident innate immune cells in the
brain, actively monitor their environment and can be-
come over-activated in response to diverse cues to pro-
duce cytotoxic factors, such as superoxide (Colton and
Gilbert, 1987), nitric oxide (Liu et al., 2002; Moss and
Bates, 2001), and tumor necrosis factor alpha (TNFa)
(Lee et al., 1993; Sawada et al., 1989). While microglial
activation is necessary and critical for host defense, over-
activation of microglia is neurotoxic (McGeer et al., 2005;
Polazzi and Contestabile, 2002). At this time, the mechan-
isms initiating deleterious neuroinﬂammation in neuro-
degenerative disease are poorly understood.
Lipopolysaccharide (LPS), endotoxin from gram-negative
bacteria, damages DA neurons only in the presence of
microglia (Gao et al., 2002; Gibbons and Dragunow, 2006).
Further, LPS activation of microglia both in vivo and in
vitro causes the progressive and cumulative loss of DA neu-
rons over time (Gao et al., 2002; Ling et al., 2002, 2006).
During critical periods of embryonic development (E 10.5),
maternal exposure to low concentrations of LPS in mice
impacts microglial activation and DA neuron survival in
offspring that persists into adulthood (Carvey et al., 2003;
Ling et al., 2006). Several of these reports indicate that due
to immunological perturbation during critical periods of de-
velopment (Ling et al., 2006) or aging and sentience
(Godbout et al., 2005), microglia can become primed, where
additional stimuli result in an exaggerated and prolonged
pro-inﬂammatory response that enhances neuron damage.
Thus, not only can microglia induce neuron damage, they
can become persistently activated to produce continuous
and uncontrolled neurotoxicity that fails to reside after the
instigating stimulus has dissipated.
Several lines of evidence suggest that adult microglia
can also become chronically activated from a single stim-
ulus in the absence of any predispositioning event or
aging. For example, chronic microglial activation con-
tinues years after brief MPTP exposure in humans (Lang-
ston et al., 1999) and primates (McGeer et al., 2003)
through a process called reactive microgliosis. Reactive
microgliosis is deﬁned by the microglial activation that
occurs in response to neuronal damage. This microglial
activation is then toxic to neighboring neurons, which
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causes further microglial activation and a self-propelling
progressive cycle of inﬂammation and neuron damage.
Regardless of the class of instigating stimuli (pro-inﬂam-
matory toxin or neuronal death) the microglial pro-inﬂam-
matory response to neuron damage can drive the progres-
sive inﬂammation and cumulative loss of neurons over
time (Block and Hong, 2005). However, neuroinﬂammation
and microglial activation is not always deleterious (Glezer
et al., 2006; Neumann et al., 2006; Simard and Rivest,
2006; Simard et al., 2006; Sriram et al., 2006). Thus, the
identiﬁcation of the stimuli and mechanisms responsible
for progressive microglial activation and associated contin-
uous neuron damage is essential to understand the etiology
and pathology of neurodegenerative diseases.
Here, we are the ﬁrst to test whether a single peripheral
LPS exposure in adult mice results in: (1) microglial activa-
tion and neuroinﬂammation that persists long after periph-
eral events have abated; (2) transfer of peripheral inﬂam-
mation to the brain through TNFa; (3) delayed and pro-
gressive loss of DA neurons in the substantia nigra (SN),
similar to PD. The results from these studies indicate that
a single occurrence of sepsis and peripheral inﬂammation
may result in self-propelling neuroinﬂammation and pro-
gressive DA neurodegeneration through TNFa.
MATERIALS AND METHODS
Animals
Eight-week male (20–22 g) B6; 129S-Tnfrsf1atm1Imx
Tnfrsf1btm1Imx/J (TNFR1/R22/2, KO) and B6; 129SF2/J
(TNFR1/R21/1, WT), and C57BL/6J mice were purchased
from Jackson Laboratories (Bar Harbor, ME). B6; 129S-
Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J (TNFR1/R22/2) mice
were lacking both the p55 and p75 TNF receptors and
maintained in B6; 129SF2/J background. Therefore, B6;
129SF2/J (TNFR1/R21/1) mice were used as strain con-
trols of TNFR1/R22/2 mice.
Reagents
Lipopolysaccharide (LPS, strain O111:B4) was purchased
from Calbiochem (San Diego, CA). The polyclonal antibody
against tyrosine hydroxylase (TH) was a kind gift from Dr.
John Reinhard of Glaxo Wellcome (Research Triangle
Park, NC). Rat monoclonal antibody raised against F4/80
antigen was purchased from Serotec (Washington, DC).
Rabbit anti-Iba1 antibody was purchased from Wako Pure
Chemical Industries (1–2Doshomachi 3-Chome Chuo-ku
Osaka 540–8605, Japan). Tumor necrosis factor alpha
(TNFa) and MCP-1 ELISA kits were purchased from R&D
Systems (Minneapolis, MN). All other reagents came from
Sigma Chemical Co. (St. Louis, MO).
Drug Treatment
Male C57BL/6J, TNFR1/R22/2, and TNFR1/R21/1 mice
were intraperitoneally injected with a single dose of LPS
(5 mg/kg), TNFa (0.25 mg/kg), or vehicle (0.9% saline).
The dosage of LPS used (5 mg/kg, i.p.) was based on our
previous study of endotoxic shock (Li et al., 2005). How-
ever, pilot studies using lower doses of LPS (1–4 mg/kg)
showed signiﬁcant increases in brain TNFa mRNA and
protein levels in a graded response (data not shown).
Mice were sacriﬁced at selected time points and tissues
(serum, brain, and liver) were used for mRNA, protein, or
morphological analyses. Procedures using laboratory ani-
mals were in accordance with the National Institutes of
Health guidelines for the use of live animals and ap-
proved by IUCAC boards.
Analysis of Neurotoxicity
The loss of dopaminergic neurons was assessed by
counting the number of TH-immunoreactive (TH-IR) neu-
rons following immunostaining of brain sections. Twenty-
four consecutive brain slices (35 lm thickness), which
encompassed the entire SNc, were collected. A normal
distribution of the number of TH-IR neurons in the SNc
was constructed based on the counts of 24 slices from
C57BL/6J mice. Eight evenly spaced brain slices from sa-
line or LPS-injected animals were immunostained with
an antibody against TH and counted. The distribution of
the cell numbers from each animal was matched with the
normal distribution curve to correct for errors resulting
from the cutting. Samples were counted in a double-bind
manner with stereology equipment, three individuals,
and the CAST system. Conclusions were drawn only
when the difference was within 5%.
Immmunohistochemistry
Brains were ﬁxed in 4% paraformaldehyde and pro-
cessed for immunostaining as described previously (Qin
et al., 2004). Dopaminergic neurons were detected with
the polyclonal antibody against tyrosine hydroxylase
(TH). Microglia was stained with rat monoclonal antibody
raised against F4/80 antigen and rabbit anti-Iba1 anti-
body, respectively. Immunostaining was visualized by
using 3,30-diaminobenzidinge and urea-hydrogen perox-
ide tablets from Sigma.
Real-Time RT-PCR Analysis
Total RNA was extracted from the mouse brain samples
treated with LPS, TNFa, or saline at the selected time
points and used for reverse transcription PCR analysis as
described previously (Qin et al., 2004). The primer
sequences used in this study were as follows: for mouse
TNFa, 50-GAC CCT CAC ACT CAG ATC ATC TTC T-30
(forward) and 50-CCT CCA CTT GGT GGT TTG CT-30
(reverse); for mouse IL-1b, 50-CTG GTG TGT GAC GTT
CCC ATT A-30 (forward) and 50-CCG ACA GCA CGA GGC
TTT-30 (reverse); for mouse NF-jB p65 (essential modula-
tor), 50-GGC GGC ACG TTT TAC TCT TT-30 (forward) and
50-CCG TCT CCA GGA GGT TAA TGC-30 (reverse); for
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mouse b-actin, 50-GTA TGA CTC CAC TCA CGG CAA A-30
(forward) and 50-GGT CTC GCT CCT GGA AGA TG-30
(reverse). The SYBR green DNA PCR kit (Applied Biosys-
tems, Foster City, CA) was used for real-time PCR analysis.
The relative differences in expression between groups were
expressed using cycle time (Ct) values normalized with b-
actin, and relative differences between control and treat-
ment groups were calculated and expressed as relative
increases setting control as 100%.
TNFa and MCP-1 Assay
Frozen livers and brains were homogenized in 100 mg
tissue/mL cold lysis buffer (20 mM Tris, 0.25 M sucrose,
2 mM EDTA, 10 mM EGTA, 1% Triton X-100) and one tab-
let of Complete Mini protease inhibitor cocktail tablets/
10 mL (Roche Diagnostics, Indianapolis, IN). Samples were
centrifuged at 100,000g for 40 min. Supernatant was col-
lected for protein assay using the BCA protein assay rea-
gent kit (PIERCE, Milwaukee, WI). The levels of TNFa
in livers, sera, and brains and MCP-1 in brains were
measured with TNFa and mouse JE/MCP-1 commercial
enzyme-linked immunosorbent assay (ELISA) kits from
R&D Systems (Minneapolis, MN), as described previously
(Gu et al., 1998).
Statistical Analysis
The data are expressed as the mean 6 SEM and statis-
tical signiﬁcance was assessed with an ANOVA followed
by Bonferroni’s t test. A value of P < 0.05 was considered
statistically signiﬁcant.
RESULTS
TNFa Response to Systemic LPS Administration
To better understand the effects of systemic LPS on
brain inﬂammation, we administered a single dose of
LPS (5 mg/kg) i.p. to male C57BL/6 mice and followed
liver, serum, and brain TNFa expression over time. LPS
increased liver TNFa mRNA 140-fold that peaked within
30 min. This was followed by liver TNFa protein increase
of 29-fold that peaked at 60 min. Serum TNFa protein
increased from 0 to 6.452 ng/mL at 60 min after LPS
treatment (see Fig. 1). Brain showed an increase in TNFa
mRNA (7,336%) and protein levels (653%) that both
peaked at 60 min. Thus, while TNFa protein levels in
response to systemic LPS peaked in the liver, serum, and
brain at 1 h, brain TNFa mRNA synthesis occurred
shortly after liver TNFa mRNA synthesis, very likely af-
ter the TNFa protein was able to enter the brain. These
results support that liver-derived TNFa was the predomi-
nant source of the immediate TNFa response to systemic
LPS (1-h post treatment) in the liver, serum, and brain,
which then initiated the synthesis of TNFa in the brain.
We also examined the long-term effects of systemic
LPS injection from several hours until 10-months post
treatment. Interestingly, serum TNFa declined to saline
control levels by 9 h (Figs. 1B, 2A). In liver, TNFa protein
levels declined to 18% of peak values by 9 h after LPS
(Figs. 1A, 2A). Surprisingly, TNFa protein remained ele-
vated in brain. At 1 week after LPS treatment TNFa
levels were elevated in brain to 319 620 pg/mg protein
compared to control values of 65 65 pg/mg protein, a
490% increase similar to the 1-h peak induction. TNFa
protein remained elevated at 14 days, 21 days, and even
10 months after LPS treatment (Fig. 2B). In addition, 3 h
after LPS treatment staining of microglia in cortex, hip-
Fig. 1. Effects of LPS treatment on liver, plasma, and brain TNFa.
Male C57BL/6 mice were treated with saline or LPS (5 mg/kg) i.p.
injection. At different time points following LPS or saline injection,
mice were sacriﬁced and brain extracts, liver extracts, and serum were
prepared as described in methods. Analysis of TNFa mRNA and protein
was conducted via real time RT-PCR and ELISA. (A) LPS rapidly
increases liver TNFa mRNA and TNFa protein. (B) Serum TNFa pro-
tein is increased after LPS treatment. (C) Brain TNFa mRNA and
TNFa protein are increased by LPS. The results are the means 6 SEM
of two experiments performed with ﬁve mice each time point. **P <
0.01, compared to the corresponding saline controls in TNFa mRNA
data. ##P < 0.01, compared to the corresponding saline controls in
TNFa protein data.
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pocampus, and SN showed microglia with enlarged cyto-
plasm and cell bodies, irregular shape, and intensiﬁed
Iba1 staining consistent with morphological activation of
microglia (see Fig. 3). In summary, these results support
an association between early (1–9 h) TNFa production in
the liver and blood, with chronic (10 months) microglial
activation in the brain.
TNFa Mediates Neuroinﬂammation in Response
to Systemic LPS and TNFa Administration
Studies indicate that TNFa is transported into brain
(Pan and Kastin, 2001; Pan et al., 2006) and that TNFa
receptors are critical for transport of the TNFa protein
from the periphery, across the blood brain barrier, and
into the brain (Pan and Kastin, 2002). To test the role of
systemic TNFa on inﬂammation in the brain, we adminis-
tered a single dose of LPS (5 mg/kg) i.p. or TNFa (0.25 mg/
kg) i.p. to male wild type B6:129SF2/J mice (WT) or male
mice deﬁcient in the TNF Type 1 and Type 2 receptors
(TNFR-KO). TNFa expression (brain, liver, and serum)
and the up regulation of other pro-inﬂammatory genes (IL-
1b, NFjB, and MCP-1) in the brain were determined.
Systemic LPS treatment increased TNFa mRNA and
protein in the liver of both WT and TNFR-KO as
expected, as LPS triggers an immune response independ-
ent of TNFa receptors (Fig. 4A). LPS increased serum
levels of TNFa in both WT and TNFR-KO mice. However,
brain TNFa mRNA and protein increased only in the WT,
but not in TNFR-KO mice, indicating that TNFa recep-
tors are necessary for peripheral LPS to cause brain
TNFa mRNA and protein production (Fig. 4C). In a sepa-
rate experiment, similar to Fig. 3, WT mice showed
increased Iba1 (a speciﬁc marker for microglia) staining
in several brain regions, such as SN, hippocampus, and
cortex (images not shown) at 2-h post LPS-treatment.
Iba1-IR cells showed increased cell size, irregular shape,
and intensiﬁed Iba1 staining consistent with morphologi-
cal changes in activated microglia. Iba1-IR cells in saline
controls in WT mice showed resting microglial morphol-
ogy. However, TNFR-KO animals did not show increased
TNFa mRNA or protein synthesis in the brain (Fig. 4C).
These ﬁndings indicate that TNFa receptors are essential
for systemic LPS administration to cause activation of
microglia and TNFa synthesis within brain.
To conﬁrm the role of systemic TNFa in brain inﬂam-
mation, WT and TNFR-KO mice were treated with TNFa
(0.25 mg/kg, i.p.). TNFa treatment resulted in a 132-fold
increase in liver TNFa mRNA and a 27-fold increase in
liver TNFa protein in WT, but not in TNFR-KO mice
(Fig. 5A). The injection of TNFa increased serum levels of
TNFa in both WT and TNFR-KO (Fig. 5B). Importantly,
systemic TNFa injection induced brain TNFa mRNA and
protein in WT, not in TNFR-KO mice (Fig. 5C). Further,
TNFa induced brain synthesis of other pro-inﬂammatory
factors, such as monocyte chemotactic protein 1 (MCP-1)
as well as NF-jB p65 subunit, interleukin-1b (IL-1b) in
WT mice. However, TNFa failed to induce production of
the pro-inﬂammatory factors in TNFR-KO mice (see Fig.
6). Thus, systemic TNFa induces pro-inﬂammatory cyto-
kine production in brain, serum, and liver, as well as
induces brain microglial activation.
A comparison of TNFa and LPS indicates these two
inﬂammatory activators are remarkably similar. Our ﬁnd-
ings suggest that systemic LPS acts by inducing TNFa syn-
thesis in the liver to increase serum TNFa, which then acti-
vates brain microglia to induce TNFa, other cytokines, and
neuroinﬂammatory protein synthesis. Taken together,
these ﬁndings suggest that an acute systemic injection of
LPS or TNFa activates brain microglia through TNFa
receptors that initiate sustained activation of brain cyto-
kine synthesis and neuroinﬂammation.
Fig. 2. Single LPS injection caused long-lasting elevated level of
TNFa protein in mouse brain. LPS (5 mg/kg) was injected intraperito-
neally in male C57BL/6 mice. At different time points following LPS or
saline injection, mice were sacriﬁced and brain extracts, liver extracts,
and serum were prepared as described in methods. (A) Comparison of
time course changes in TNFa protein in liver, serum and brain. Each
tissue is adjusted to set peak values as 100%. Note that the liver and
serum peak and decline in parallel, whereas, the brain remains ele-
vated for at least 10 months. (B) Long term time course of LPS induced
increases in TNFa protein in brain. TNFa levels peaked at 1 h and
remained elevated for 10 months. The results are the means 6 SEM of
two experiments performed with ﬁve mice each time point.**P < 0.01,
compared to the corresponding saline controls.
456 QIN ET AL.
GLIA DOI 10.1002/glia
Peripheral Inﬂammation Induces a Delayed
and Progressive Loss of Dopaminergic Neurons
in the Substantia Nigra
The substantia nigra (SN) is densely populated with
microglia (Kim et al., 2000; Lawson et al., 1990) and it is
hypothesized that this brain region is particularly suscep-
tible to inﬂammatory insult. To discern the effects of
chronic neuroinﬂammation (sustained increase in brain
TNFa for at least 10 months) on neuron survival in the
SN, we measured the number of dopamine neurons, as
indicated by the number of tyrosine hydroxylase immuno-
reactive (TH-IR) cells within the SN, after a single LPS
i.p. treatment. Previous reports using intranigral injec-
tion of LPS demonstrated that the LPS-induced decline of
TH-IR cells is due to cell loss, as evidenced by a decline in
the over-all number of neurons in the SN (Gao et al.,
2002). As shown in Fig. 7, LPS injection caused a delayed
and progressive loss of nigral TH-IR neurons. Compari-
son of the number of nigral TH-IR neurons between the
LPS-treated and saline-treated mice showed no signiﬁ-
cant loss of TH-IR neurons within the ﬁrst 4 months after
LPS injection (Fig. 7A). However, signiﬁcant loss of TH-
IR neurons started to manifest between 7 and 10 months
after LPS treatment. At 7 months, a 23% loss was
observed. The LPS-induced loss of nigral TH-IR neurons
further progressed over time and a 47% loss was shown
at 10 months (Fig. 7A). Using double labeled (TH-IR and
NeuN-IR) staining, we have previously reported that
inﬂammation-induced loss of TH-IR cells in the nigra
represents neuronal death, rather a down regulation of
TH expression (Gao et al., 2002). Changes in TH-IR cells
were more pronounced in SN than in the adjacent ventral
tegmental area (VTA) DA neurons (Fig. 7B). Interest-
ingly, staining for microglia using F4/80 antibody indi-
cated that the SN contains much more microglia than the
adjacent VTA (Fig. 7C). Cell loss in other brain regions
was not determined. Thus, the SN may be inherently sus-
ceptible to inﬂammatory insult when compared to other
regions of the basil ganglia due to the presence of
increased microglia. These studies support the hypothesis
that an acute increase in systemic TNFa activates neu-
Fig. 3. Immunocytochemical analysis of microglia.
C57BL/6 mice were sacriﬁced 3 h following saline or LPS
(5 mg/kg) i.p. injection. Brain sections were immnostained
with Iba1 speciﬁc microglial antibody. Activated microglia
in substantia nigra, hippocampus and cortex were shown
by increased cell size, irregular shape, and intensiﬁed
Iba1 staining in LPS-treated mouse brains. The images
are from one experiment that is representative of three
separate experiments.
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roinﬂammatory processes within brain that are sustained
for long periods, which leads to delayed and progressive
degeneration of DA neurons.
DISCUSSION
The mechanisms responsible for the progressive loss of
DA neurons in PD are poorly understood. Here, we are
the ﬁrst to show that a single exposure to systemic
inﬂammation transfers to the brain and initiates self-pro-
pelling neuroinﬂammation that persists for 10 months,
which results in the progressive loss of DA neurons in the
SN (see Fig. 8). Speciﬁcally, we investigated three aspects
of peripheral LPS administration: the role of TNFa in the
Fig. 4. Comparison of LPS-induced changes in TNFa in TNFR1/
R21/1 (WT) and TNFR1/R22/2 (KO) mice. TNFa mRNA and protein
were measured 1 h after saline or LPS (5 mg/kg) i.p. injection. (A) LPS
activated liver TNFa mRNA (left legend-solid bars) and TNFa protein
(right legend-striped bars) in both wild type (WT) mice and mice lack-
ing TNFa receptors (KO). (B) Serum TNFa protein is elevated by LPS
in both WT and KO mice. (C) TNFa mRNA and protein was elevated in
WT mice, but not in KO mice. These results indicate that TNFa recep-
tors in brain are essential for LPS induced elevations of brain TNFa,
but not for LPS induced elevations of liver TNFa. The results are the
means 6 SEM of two independent experiments performed with six
mice for each treatment. *P < 0.05, **P < 0.01, compared to the corre-
sponding saline controls.
Fig. 5. Effects of systemic TNFa on liver, serum and brain TNFa in
TNFR1/R21/1 (WT) and TNFR1/R22/2 (KO) mice. Animals were sacri-
ﬁced 1 h following saline or TNFa (0.25 mg/kg) i.p. injection. TNFa
mRNA and protein was measured via real time RT-PCR and ELISA.
(A) Wild type mice show a marked increase in liver TNFa mRNA (solid
bars-left legend) and protein (striped bars-right legend) 1 h after TNFa
treatment, but not TNFR1/R2 KO mice. (B) All mice injected with
TNFa show increased serum levels of TNFa. (C) In wild type mice sys-
temic TNFa injection markedly increases brain TNFa mRNA (solid
bars-left legend) and protein (striped bars-right legend), but not
TNFR1/R2 knock out mice. The results are the means 6 SEM of two
independent experiments performed with six mice for each treatment.
*P < 0.05, **P < 0.01, compared to the corresponding saline controls.
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transfer of systemic inﬂammation to the brain, the dura-
tion of neuroinﬂammation, and the neurotoxic conse-
quences for DA neurons in the SN.
Peripheral Inﬂammation Causes Chronic
Neuroinﬂammation Through TNFa
In the current study, we demonstrate that a single in-
traperitoneal LPS injection results in TNFa production
in the periphery, which initiates brain TNFa production
(mRNA and protein) in the brain that continues for
months after the systemic source of TNFa has abated. It
was previously reported that liver is the major source for
the circulating TNFa after a single systemic LPS injec-
tion, due to activation of kupffer cells, the resident macro-
phage-like cells in the liver (Kumins et al., 1996). These
cytokines are then released into the blood and induce
inﬂammation throughout the body (Crews et al., 2006).
Here, we found that liver and serum TNFa were elevated
at early time points, but declined over time to return to
basal levels by 1 week and 9 h, respectively. Remarkably,
TNFa levels remained elevated in the brain for up to 10
months, long after liver and serum levels had subsided.
Further, immunohistochemical analysis of brain sections
showed that microglia was activated in several brain
regions, such as the SN, hippocampus, and cortex. Previ-
ous reports have shown that a single exposure to MPTP,
a toxin selective for DA neurons, in humans (Langston
et al., 1999) and monkeys (McGeer et al., 2003) resulted
in microglial activation that persisted years after the
brief exposure. Earlier studies investigating the long-
term effects of systemic LPS exposure in utero has shown
that low levels of systemic inﬂammation must occur dur-
ing a critical window of development in order for the long
lasting, pro-inﬂammatory changes in the brain to occur
(Carvey et al., 2003; Ling et al., 2002). Our current work
indicates that a single pro-inﬂammatory event in the pe-
riphery can induce chronic, self-propelling neuroinﬂam-
mation outside of the embryonic critical period and in the
adult brain.
It is well-documented that in the normal condition,
very little peripheral LPS enters to the brain due to the
poor passage through the blood brain barrier (Nadeau
and Rivest, 1999). Thus, the LPS-induced neuroinﬂam-
mation is likely an indirect effect. In an effort to under-
stand how chronic neuroinﬂammation was transferred
from the periphery to the brain, we administered TNFa
peripherally and found that both systemic TNFa and
LPS administration increased the expression of brain
pro-inﬂammatory factors (TNFa, MCP-1, IL-1b, and NF-
jB p65) in a similar pattern. Further, TNFR1/R22/2 mice
failed to show brain neuroinﬂammation in response to
systemic LPS or systemic TNFa, supporting that TNFa
was critical for the transfer of inﬂammation from the pe-
riphery to the CNS. This is consistent with other studies
demonstrating that systemic cytokines mediate the
effects of peripheral inﬂammation on the brain. For
example, TNFa and other systemic cytokines are
reported to mimic several behavioral effects of systemic
LPS (Berkenbosch et al., 1987; Bernardini et al., 1990;
Sapolsky et al., 1987; Sharp et al., 1989). Thus, systemic
cytokines are critical for CNS effects in response to pe-
ripheral immune activation.
Here, we are the ﬁrst to show chronic neuroinﬂamma-
tion and progressive neurodegeneration a single injection
of LPS. Currently, the detailed mechanisms of this pro-
gressive neuroinﬂammation are unknown. However, we
speculate that the initial entry of the pro-inﬂammatory
factors, such as TNFa to the brain will cause the activa-
tion of microglia to produce more inﬂammatory factors,
which may cause neuronal death. Upon exposure to
TNFa, microglia are well known to synthesize and secrete
TNFa (Rivest et al., 2000). Thus, this initial damage may
then result in reactive microgliosis, causing the release of
additional pro-inﬂammatory factors to begin a self-pro-
pelling and a vicious cycle of neuronal damage. We pro-
pose that reactive microgliosis may underlie the progres-
sive and long-lasting neuroinﬂammation and neuro-
degeneration of numerous neurodegenerative diseases
(Block and Hong, 2005).
Fig. 6. Systemic TNFa increases IL-1b, NF-jB, and MCP-1 expres-
sion in TNFR1/R21/1 (WT) mice. TNFR1/R21/1 (WT) and TNFR1/R22/2
(KO) mice were injected with saline or TNFa (0.25 mg/kg) intraperito-
neally. Brain mRNA expression of IL-1b and NF-jB-p65 and MCP-1
protein content were measured using real-time PCR and ELISA 1 h fol-
lowing saline or TNFa treatment. (A) Brain mRNA expression of IL-1b
and NF-jB-p65 is increased by systemic TNFa in wild type mice, but
not in TNFa receptor double KO mice. (B) Systemic TNFa administra-
tion increases brain MCP-1 protein in WT mice, but not in TNFR-KO
mice. The results are the means 6 SEM of two independent experi-
ments performed with six mice for each treatment. *P < 0.05, **P <
0.01, compared to the corresponding saline control mice.
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Peripheral Inﬂammation Causes Progressive
Dopaminergic Neurotoxicity
Inﬂammation is implicated as a neurodegenerative
stimulus (Maurizi, 2002) and DA neurons in the SN are
thought to be more susceptible to inﬂammation when
compared to other neuronal subtypes and other brain
regions (Block and Hong, 2005; Carvey et al., 2003; Gao
et al., 2002; Ling et al., 2002). Microglial activation has
been shown to induce the selective loss of DA neurons in
response to multiple stimuli (Block et al., 2004; Wu et al.,
2005; Zhang et al., 2005), including LPS (Gao et al., 2002;
Ling et al., 2002, 2004a,b, 2006). Additionally, the SN
contains 4.5 times as many microglia when compared to
other brain regions (Kim et al., 2000), making this region
particularly susceptible to inﬂammatory insult. In the
current study, we have stained the SN for microglia and
document that there are visibly more microglia in the
SN, when compared to the VTA and other brain regions
(see Fig. 7), helping to explain why global neuroinﬂam-
mation can result in selective damage. Previously, it has
been shown that a single injection of the selective dopa-
minergic neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP), results in chronic neuroinﬂamma-
tion and progressive neurotoxicity in humans (Langston
et al., 1999) and monkeys (McGeer et al., 2003), where
the mechanisms of microglial activation and progressive
toxicity are poorly deﬁned. Here, we show that a single
systemic administration of LPS results in signiﬁcant loss
of DA neurons beginning at 7-months post treatment
(23% loss of TH-IR neurons) and increasing in severity
with time to a 47% loss at 10-months post treatment.
Thus, we are the ﬁrst to show that a single pro-inﬂamma-
tory stimulus from the periphery in the adult mouse
results in delayed and progressive loss of DA neurons in
the SN (over months), similar to what occurs in PD. This
is consistent with a previous report of a single human
case study where accidental peripheral administration of
LPS was associated with later onset of PD (Niehaus,
2003). The delayed onset, progressive nature, and long-
lasting DA neuronal degeneration after a single injection
of LPS shown in this study suggests a clinical implication
for the link between peripheral inﬂammation and neu-
roinﬂammation. Thus, it would be interesting to deter-
Fig. 7. Delayed and time-dependent loss of nigral
dopaminergic neurons following LPS i.p. injection.
Male C57BL/6 mice were treated with saline or LPS (5
mg/kg, i.p.) and then maintained under normal condi-
tions for the indicated time points. Mice were sacri-
ﬁced and brain sections (35 mm thick) were cut
through the nigral complex. After immunostaining
with TH antibody, the number of TH-IR neurons in
the SN was counted as described in methods. Results
are expressed as percentage of the corresponding sa-
line controls. (A) Number of TH-IR neurons in the SN
of control and LPS-treated mice at different time
points. (B) Visualization of TH-IR neurons in the sub-
stantia nigra and ventral tegmental area of saline and
LPS-treated animals at 10 months. (C) F4/80-Immuno-
histochemistry for microglia within the SN and VTA of
saline and LPS treated animals at 10 months. Note
the high density of F4/80-IR microglia in the substan-
tia nigra associated with the loss of dopaminergic neu-
rons in mice treated with LPS. **P < 0.01, compared
to the saline controls (n 5 8–10 per time point).
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mine epidemiologically whether there is a link between
patients surviving septic shock and the incidence of PD.
Several studies indicate that pro-inﬂammatory events
occurring peripherally can inﬂuence neurotoxicity. The
majority of previous reports demonstrate that systemic
inﬂammation can amplify an inﬂammatory stimulus and
consequent neuronal damage. For example, systemic
administration of LPS enhanced motor neuron degenera-
tion in animal models of amyotrophic lateral sclerosis at
6 months (Nguyen et al., 2004), but no direct toxic effect
of systemic LPS alone was reported. Systemic exposure to
LPS in the neonate was also shown to signiﬁcantly
amplify neuronal death associated with ischemic insult
(Lehnardt et al., 2003). Interestingly, it is suggested that
peripheral inﬂammation could be protective, as one study
has shown that neuroinﬂammation induced by intrastria-
tal injection of endotoxin could be blocked by systemic
LPS administration, where the protection was mediated
through LPS-induced plasma corticosterone (Nadeau and
Rivest, 2002). In the current study, we demonstrate that
a high dose of systemic LPS (5 mg/kg) can actively induce
persistent inﬂammation and progressive neurotoxicity
over 10 months in the adult animal. Thus, the effects of
peripheral inﬂammation on neuron survival may depend
upon several factors, such as brain region examined,
length of time investigated to allow cumulative effects,
age of exposure to the inﬂammagen, presence of systemic
TNFa, and severity of the inﬂammatory stimuli tested.
In summary, our study supports that LPS activates
cells in the liver to produce TNFa, which is distributed in
the blood and transferred to the brain through TNFa
receptors to induce the synthesis of additional TNFa and
other pro-inﬂammatory factors, creating a persistent and
self-propelling neuroinﬂammation that induces delayed
and progressive loss of DA neurons in SN of adult ani-
mals. This work offers strong support for the premise
that inﬂammation is both an initiating stimulus and a
self-propelling mechanism of progressive neurondegen-
eration.
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